Journal of Neuro-Oncology

, Volume 79, Issue 2, pp 159–168 | Cite as

Proposal of a scoring scale as a survival predictor in intracranial oligodendrogliomas

  • Abderrahmane Hamlat
  • Stephan Saikali
  • Jacques Chaperon
  • Beatrice Carsin-Nicol
  • Michéle Le Calve
  • Thierry Lesimple
  • Mohamed Ben-hassel
  • Yvon Guegan
Clinical-patient studies



Histological, clinical and radiological features, and molecular genetic analysis are among the factors that have been considered in defining the prognosis of oligodendrogliomas (OD), but they have yielded conflicting results.

The purpose of this study was to test out a scoring scale based on clinical, radiological, pathological and molecular features.

Material and method

To identify factors with prognostic significance, we analyzed 87 treated patients with a histological diagnosis of OD. Of the parameters analyzed, age, onset, clinical status, radiological enhancement, histological necrosis, mitosis and chromosomal anomalies emerged as significant prognosis factors using univariate analysis. Multivariate analysis revealed age and chromosomal anomalies as independent factors of survival.


The factors with a significant prognostic value were combined to determine which grouping factors best predict outcome. The proposed score is a pure number resulting from a combination of: 2 major factors: age and chromosomal anomalies (scored 3–0); 5 minor factors: onset, clinical examination, necrosis, mitoses (scored 1–0), and radiological enhancement (scored 2–0). According to our scale, 10 survival curves were produced for overall survival. Recursive partitioning of patients with the nearest score and outcome produced four groups with a significant difference in survival (p=10−5). The power of both the scale and the partitioned groups for predicting outcome was more accurate than the WHO and St Anne grading systems, and the molecular sub-classification.


Our scale is a plausible way of classifying patients harboring intracranial OD according to expected survival.


grading intracranial tumor oligodendroglioma prognosis scale 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.



We are grateful to Abed El-Ghalem for his help and advice and Ms. T. Westcott for correcting the English. In memory of Larbi Hamlat.


  1. 1.
    Engelhard HH, Stelea A, Cochran EJ, Oligodendroglioma: pathology and molecular biology Surg Neurol 58:111–117; 2002PubMedCrossRefGoogle Scholar
  2. 2.
    Fortin D, Cairncross GJ, Hammond RR, Oligodendroglioma: an appraisal of recent data pertaining to diagnosis and treatment Neurosurgery45:1279–1291; 1999PubMedCrossRefGoogle Scholar
  3. 3.
    Reifenberger G, Louis DN, Oligodendroglioma: toward molecular definitions in diagnostic neuro-oncology. J Neuropath Exp Neurol 62:111–126; 2003PubMedGoogle Scholar
  4. 4.
    Daumas-Duport C, Varlet P, Tucker ML, Beuvon F, Cervera P, Chodkiewicz JP Oligodendrogliomas. Part I, patterns of growth, histological diagnosis, clinical and imaging correlations: a study of 153 cases J Neuro-Oncol 34:37–59; 1997CrossRefGoogle Scholar
  5. 5.
    Deghani F, Schachenmayr W, Laun A, Korf HW, Prognostic implication of histopathological, immunohistochemical and clinical features of oligodendrogliomas: a study of 89 cases Acta Neuropathol95:493–504; 1998CrossRefGoogle Scholar
  6. 6.
    Korshunov A, Golanov A, The prognostic significance of vascular endothelial growth factor (VEGF C-1) immunoexpression in oligodendroglioma: an analysis of 91 casesJ Neuro-Oncol48:13–19; 2000CrossRefGoogle Scholar
  7. 7.
    Jeremic B, Shibamoto Y, Grujicic D, Milicic B, Stojanovic M, Nikolic N, Dagovic A, Aleksandrovic J, Combined treatment modality for anplastic oligodendroglioma: a phase II study J Neuro-Oncol43:179–185; 1999CrossRefGoogle Scholar
  8. 8.
    Perry JR, Louis D, Cairncross JG, Current treatment of oligodendrogliomas Arch Neurol56:434–436; 1999PubMedCrossRefGoogle Scholar
  9. 9.
    Shimizu KT, Tran LM, Mark RJ, Selch MT, Management of oligodendrogliomasRadiology186:569–572; 1993PubMedGoogle Scholar
  10. 10.
    Wallner KE, Gonzales M, Sheline GE, Treatment of oligodendrogliomas with or without postoperative irradiation J Neurosurg68:684–688; 1988PubMedGoogle Scholar
  11. 11.
    Celli P, Nofrone I, Palma L, Cantore G, Fortuna A, Cerebral oligodendroglioma: prognostic factors and life history Neurosurgery35:1018–1025; 1994PubMedCrossRefGoogle Scholar
  12. 12.
    Lindegaard KF, Mork SJ, Eide GE, Halvorsen TB, Hatlevoll R, Solgaard T, Dahl O, Ganz J, Statistical analysis of clinicopathological features, radiotherapy, and survival in 170 cases of oligodendrogliomaJ Neurosurg67:224–230; 1987PubMedCrossRefGoogle Scholar
  13. 13.
    Mork SJ, Lindegaard KF, Halvorsen TB, Lehmann EH, Solgaard T, Hatlevoll R, Harvei S, Ganz J, Oligodendroglioma: incidence and biological behaviour in a defined population J Neurosurg63:881–889; 1985PubMedGoogle Scholar
  14. 14.
    Shaw EG, Scheithauer BW, O’Fallon JR, Tazelaar HD, Davis DH, Oligodendrogliomas: the Mayo Clinic experience J Neurosurg76:428–434; 1992PubMedCrossRefGoogle Scholar
  15. 15.
    Sun ZM, Genka S, Shitara N, Akanuma A, Takakura K, Factors possibly influencing the prognosis of oligodendroglioma Neurosurgery22:886–891; 1988PubMedCrossRefGoogle Scholar
  16. 16.
    Van den Bent M, Chinot OL, Cairncross JG, Recent developments in the molecular characterization and treatment of oligodendroglial tumors Neuro-Oncol 5:128–138; 2003PubMedCrossRefGoogle Scholar
  17. 17.
    Yeh SA, Lee TC, Chen HJ, Lui CC, Sun LM, Wang CJ, Huang EY, Treatment outcomes and prognostic factors of patients with supratentorial low-grade oligodendroglioma Int J Radiation Oncology Biol Phys54:1405–1409; 2002CrossRefGoogle Scholar
  18. 18.
    Pirzkall A, Nelson SJ, McKnight TR, Takahashi MM, Li X, Graves EE, Verhey LJ,Wara WW, Larson DA, Sneed PK, Metabolic imaging of low-grade gliomas with three-dimensional magnetic resonancespectroscopy Int J Radiat Oncol Biol Phys53:1254–1264; 2002PubMedCrossRefGoogle Scholar
  19. 19.
    Vaquero J, Zurita M, Morales C, Coca S, Prognostic significance of tumor-enhancement and angiogenesis in oligodendroglioma Acta Neurol Scand106:19–23; 2002PubMedCrossRefGoogle Scholar
  20. 20.
    Leonardi MA, Lumenta CB, Oligodendrogliomas in the CT/MR-era Acta Neurochir (Wien)143:1195–1203; 2001CrossRefGoogle Scholar
  21. 21.
    Ino Y, Betensky RA, Zlatescu MC, Sasaki H, Mcdonald DR, Stemmer-Rachamimov AO, Ramsay DA, Cairncross JG, Louis DN, Molecular subtypes of anaplastic oligodendroglioma: implications for patient management at diagnosis Clin Cancer Res7:839–845; 2001PubMedGoogle Scholar
  22. 22.
    Diabira S, Rousselet MC, Gamelin E, Soulier P, Jadaud E, Menei P, PCV chemotherapy for oligodendroglioma: response analyzed on T2 weighted-MRI J Neuro-Oncol55:45–50; 2001CrossRefGoogle Scholar
  23. 23.
    Giammarile F, Cinotti LE, Jouvet A, Ramackers JM, Saint Pierre G, Thiesse P, Jouanneau E, Guyotat J, Pelissou-Guyotat I, Setiey A, Honnorat J, Le Bars D, Frappaz D, High and low grade oligodendroglioma(ODG): correlation of amino-acid and glucose uptakes using PET and histological classifications J Neuro-Oncol68:263–274; 2004CrossRefGoogle Scholar
  24. 24.
    Alvord EC Jr, Is necrosis helpful in the grading of gliomas? Editorial opinion. J Neuropathol Exp Neurol 51:127–132; 1992PubMedCrossRefGoogle Scholar
  25. 25.
    Daumas-Duport C, Tucker ML, Kolles H, Cervera P, Beuvon F, Varlet P, Udo N, Koziak M, Chodkiewicz JP Part II. A new grading system based on morphological and imaging criteria J Neuro-Oncol34:61–78; 1997CrossRefGoogle Scholar
  26. 26.
    Kros JM, Troost D, Eden CG, Van Der Werf AJM, Uylings HBM, Oligodendroglioma: a comparison of two grading systemsCancer61:2251–2259; 1988PubMedCrossRefGoogle Scholar
  27. 27.
    Prayson RA, DS Mohan, Song P, Suh JH, Clinocopathologic study of forty-four histologically pure supratentorial oligodendrogliomas Ann Diagn Pathol 4:218–227; 2000PubMedCrossRefGoogle Scholar
  28. 28.
    Vaquero J, Zurita M, Coca S, Oya S, Morales C, Prognostic significances of clinical and angiogenesis-related factors in low-grade oligodendrogliomasSurg Neurol54:229–234; 2000PubMedCrossRefGoogle Scholar
  29. 29.
    Bigner SH, Matthews MR, Rasheed BKA, Wiltshire RN, Friedman HS, Friedman AH, Stenzel TT, Dawes DM, McLendon RE, Bigner DD, Molecular genetic aspects of oligodendrogliomas including analysis by comparative genomic hybridizationAm J Pathol155:375–386; 1999PubMedGoogle Scholar
  30. 30.
    Cairncross JG, Ueki K, Zlatescu MC, Lisle DK, Finkelstein DM, Hammond RR, Silver JS, Stark PC, Macdonald DR, Ino Y, Ramsay DA, Louis DN, Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas J Natl Cancer Inst90:1473–1479; 1998PubMedCrossRefGoogle Scholar
  31. 31.
    Nutt CL, Mani DR, Betensky RA, Tamayo P, Cairncross JG, Ladd C, Pohl U, Hartmann C, McLaughlin ME, Batchelor TT, Black PM, Von Deimling A, Pomeroy SL, Golub TR, Louis D, Gene expression-based classification of malignant gliomas correlates better with survival than histological classification Cancer Res63:1602–1607; 2003PubMedGoogle Scholar
  32. 32.
    Jeuken JWM, Sprenger SHE, Wermeer H, Kapelle AC, Boerman RH, Wesseling P, Chromosomal imbalances in primary oligodendroglial tumors and their recurrences: clues about malignant progression detected using comparative genomic hybridization J Neurosurg96:559–564; 2002PubMedGoogle Scholar
  33. 33.
    Watson MA, Perry A, Budhjara V, Hicks C, Shannon WD, Rich KM, Gene expression profiling with oligonucleotide microarrays distinguishes World Heath Organization grade of oligodendrogliomas Cancer Res61:1825–1829; 2001PubMedGoogle Scholar
  34. 34.
    Nigro JM, Takahashi MA, Ginzinger DG, Law M, Passe S, Jenkins RB, Aldape K, Detection of 1p and 19q loss in oligodendroglioma by quantitative microsatellite analysis, a real time quantitative polymerase chain reaction assay Am J Pathol158:1253–1262; 2001PubMedGoogle Scholar
  35. 35.
    Smith JS, Perry A, Borell TJ, Lee HK, O’Fallon J, Hosek SM, Kimmel D, Yates A, Burger PC, Scheithauer BW, Jenkins RB, Alterations of chromosome arms 1p and 19q as predictors survival in oligodendrogliomas, astrocytomas and mixed oligoastrocytomas J Clin Oncol18:636–645; 2000PubMedGoogle Scholar
  36. 36.
    Zlatescu MC, TehraniYazdi R, Sasaki H, Megyesi JF, Betensky RA, Louis DN, Cairncross JG, Tumor location and growth pattern correlate with genetic signature in oligodendroglial neoplasmsCancer Res61:6713–6715; 2001PubMedGoogle Scholar
  37. 37.
    Kleihues P, Louis DN, Scheithauer BW, Rorke L, Reifenberger G, Burger PC, Cavenee WK, The WHO classification of tumors of the nervous system J Neuropathol Exp Neurol61:215–225; 2002PubMedGoogle Scholar
  38. 38.
    Mark HFL, Fluorescence in situ hybridization as an adjunct to conventional cytogenetics Ann Clin Lab Sci24:153–163; 1994PubMedGoogle Scholar
  39. 39.
    Smith JS, Alderete B, Minn Y, Borell TJ, Perry A, Mohapatra G, Hosek SM, Kimmel D, O’Fallon J, Yates A, Feuerstein BG, Burger PC, Scheithauer BW, Jenkins RB, Localization of common deletion regions on 1p and 19q in human gliomas and their association with histological subtype Oncogene18: 4144–4152; 1999PubMedCrossRefGoogle Scholar
  40. 40.
    Smith MT, Ludwig CL, Godfrey AD, Armbrustmacher VW, Grading oligodendrogliomas Cancer52: 2107–2114; 1983PubMedCrossRefGoogle Scholar
  41. 41.
    Coons SW, Johnson PC, Scheithauer BW, Yates AJ, Pearl DK, Improving diagnostic accuracy and interobserver concordance in the classification and grading of primary gliomas Cancer79:1381–1393; 1997PubMedCrossRefGoogle Scholar
  42. 42.
    Prayson RA, Castilla EA, Hembury TA, Liu W, Noga CM, Prok AL, Interobserver variability in determining MIB-1 labeling indices in oligodendroglioma Ann Diagn Pathol7:9–13; 2003PubMedCrossRefGoogle Scholar
  43. 43.
    Kearney L Molecular cytogenetics Best Practice & ResearchClin Haematol 14:645–668; 2001Google Scholar

Copyright information

© Springer science + business media 2006

Authors and Affiliations

  • Abderrahmane Hamlat
    • 1
    • 8
  • Stephan Saikali
    • 2
  • Jacques Chaperon
    • 3
  • Beatrice Carsin-Nicol
    • 4
  • Michéle Le Calve
    • 5
  • Thierry Lesimple
    • 6
  • Mohamed Ben-hassel
    • 7
  • Yvon Guegan
    • 1
  1. 1.Department of NeurosurgeryCHU PontchaillouRennesFrance
  2. 2.Departments of PathologyCHU PontchaillouRennesFrance
  3. 3.Departments of Public HealthCHU PontchaillouRennesFrance
  4. 4.Departments of RadiologyCHU PontchaillouRennesFrance
  5. 5.Department of Cytogenetic and Molecular BiologyCHU PontchaillouRennesFrance
  6. 6.Departments of Medical OncologyCentre Eugene MarquisRennesFrance
  7. 7.Departments of RadiotherapyCentre Eugene MarquisRennesFrance
  8. 8.Service de neurochirurgieCHRU PontchaillouRennes Cedex 2France

Personalised recommendations